AstraZeneca Still Not Done Cutting Costs

Biopharma groups seek changes to FDA’s innovative manufacturing strategy

Sanofi CD38 antibody delivers in phase 3 trial

Pfizer to let go of 791 employees at NJ site

Novartis completes Sandoz spin-off